Megan Johnson Fitzpatrick, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, T-Cell, Peripheral | 2 | 2021 | 125 | 1.330 |
Why?
|
| Chylous Ascites | 1 | 2022 | 21 | 0.800 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2021 | 168 | 0.660 |
Why?
|
| Gene Fusion | 1 | 2021 | 356 | 0.610 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 460 | 0.610 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 561 | 0.590 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 1141 | 0.520 |
Why?
|
| Pancreas | 2 | 2020 | 1699 | 0.500 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 659 | 0.440 |
Why?
|
| Triage | 1 | 2020 | 995 | 0.420 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 2952 | 0.380 |
Why?
|
| Pancreatic Neoplasms | 2 | 2020 | 5446 | 0.380 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 1759 | 0.310 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 3626 | 0.270 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2023 | 121 | 0.210 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 5186 | 0.210 |
Why?
|
| Poly(A)-Binding Protein I | 1 | 2021 | 15 | 0.190 |
Why?
|
| Hematologic Diseases | 1 | 2023 | 498 | 0.160 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 751 | 0.150 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2022 | 1131 | 0.140 |
Why?
|
| Needles | 1 | 2020 | 461 | 0.140 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1864 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 14672 | 0.130 |
Why?
|
| Translocation, Genetic | 1 | 2021 | 1391 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 1776 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2022 | 4114 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2022 | 81659 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 59548 | 0.090 |
Why?
|
| Middle Aged | 6 | 2022 | 223233 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 11063 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2021 | 3591 | 0.070 |
Why?
|
| Humans | 10 | 2023 | 767040 | 0.070 |
Why?
|
| Aged | 4 | 2021 | 171319 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2023 | 8940 | 0.070 |
Why?
|
| Male | 6 | 2022 | 364203 | 0.070 |
Why?
|
| Phenotype | 1 | 2021 | 16718 | 0.050 |
Why?
|
| Cell Shape | 1 | 2023 | 372 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4881 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 18063 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 39317 | 0.040 |
Why?
|
| Female | 4 | 2021 | 396660 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 30211 | 0.040 |
Why?
|
| Adult | 2 | 2021 | 223317 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 3212 | 0.020 |
Why?
|
| Hospitals | 1 | 2020 | 3883 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 20169 | 0.020 |
Why?
|
| Prognosis | 1 | 2023 | 29963 | 0.010 |
Why?
|